CVS Health Corp. Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. CVS Health operates as an integrated health solutions company with four reportable segments: Health Care Benefits (Aetna), Health Services (CVS Caremark), Pharmacy & Consumer Wellness (CVS Pharmacy), and Corporate/Other. As of the reporting date, the company operated approximately 9,000 retail locations and served approximately 88 million pharmacy benefit plan members and 37 million health insurance members.
Key Financial Metrics
| Metric (in millions) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $100,426 | $94,588 |
| Operating Income | $4,680 | $3,374 |
| Net Income (Attributable to CVS) | $2,943 | $1,779 |
| Diluted EPS | $2.30 | $1.41 |
| Operating Cash Flow | $4,249 | $4,556 |
| Cash & Equivalents (End of Period) | $9,542 | $8,453 |
| Long-Term Debt | $60,531 | $60,502 |
Margins: Operating margin improved to 4.7% in Q1 2026 compared to 3.6% in Q1 2025. The effective income tax rate was 24.9% for the quarter.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 6.2% ($5.8 billion) year-over-year, driven by growth across all operating segments. Product revenues rose 7.9% and Premiums rose 3.0%.
- Profitability Surge: Net income attributable to CVS Health increased 65.4% ($1.16 billion). This significant jump was primarily due to the absence of one-time charges recorded in Q1 2025, specifically a $387 million legacy litigation charge and a $247 million loss on the wind-down of Accountable Care assets.
- Segment Performance:
- Health Care Benefits: Adjusted operating income increased 52.6% to $3.0 billion, aided by improved government business performance and the absence of a $448 million premium deficiency reserve recorded in the prior year.
- Health Services: Revenues grew 11.0% to $48.2 billion, though adjusted operating income declined 7.1% due to client price improvements.
- Pharmacy & Consumer Wellness: Revenues were flat (0.2% increase), but operating income rose 31.3% due to the absence of the prior year's litigation charge.
- Cash Flow: Operating cash flow decreased 6.7% to $4.2 billion, attributed to the timing of payments and receipts.
Outlook, Risks, and Contingencies
Guidance and Commentary: Management noted that utilization levels persisted at elevated levels in Q1 2026, which may pressure the Health Care Benefits segment. The company continues to share a larger portion of rebates with clients and faces pressure from pharmaceutical manufacturers regarding rebate calculations. No specific forward-looking financial guidance was provided in this text.
Legal and Regulatory Risks:
- Opioid Litigation: The company has a remaining accrual of approximately $4.0 billion related to opioid litigation settlements. A new trial regarding Florida hospitals is scheduled for August 2026.
- PBM Investigations: In March 2026, CVS and the FTC executed a proposed settlement agreement regarding PBM practices (rebates, network, vertical integration). The settlement is under consideration by the Commission.
- Prescription Processing: A litigation reserve of $165 million remains on the balance sheet related to joint and several liability for penalties in the Omnicare case.
- Regulatory Trends: The company faces potential legislative changes regarding PBM activities and pharmacy licensure in various states, as well as ongoing CMS audits of risk-adjustment data.
Capital Allocation: The company did not repurchase any shares in Q1 2026. The quarterly dividend remained $0.665 per share. Approximately $11.5 billion remains available under authorized share repurchase programs.
Investor Verification Checklist
- Verify the status and final terms of the proposed FTC settlement regarding PBM practices.
- Monitor the outcome of the Florida hospital opioid trial scheduled for August 2026 and potential impacts on the $4.0 billion accrual.
- Assess the impact of elevated medical utilization trends on the Health Care Benefits segment's Medical Benefit Ratio (MBR) in subsequent quarters.
- Review the integration progress and financial contribution of the Rite Aid asset acquisitions completed in late 2025.
- Track the resolution of the Omnicare bankruptcy and the status of the $165 million joint liability reserve.